Monitoring honeybee venom immunotherapy in children with the basophil activation test

Authors


Assistant Professor Peter Korošec, University Clinic of Respiratory and Allergic Diseases, Laboratory for Clinical Immunology & Molecular Genetics, Golnik 36, 4204 Golnik, Slovenia
Tel.: +386 4 256 9432
Fax: +386 4 256 9143
E-mail: peter.korosec@klinika-golnik.si

Abstract

To cite this article:Žitnik SEK, Vesel T, Avčin T, Šilar M, Košnik M, Korošec P. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr Allergy Immunol 2011 Doi: 10.1111/j.1399-3038.2011.01233.x

Abstract

Background:  New in vitro methods are essential for developing better follow-up criteria for venom immunotherapy (VIT).

Methods:  Thirty-one children with a history of honeybee venom–induced systemic anaphylaxis were included in this prospective, single-blinded study. The basophil CD63 activation test (BAT) was assessed before starting VIT, at the end of the build-up phase (day 5), 6 months later, and after 2–4 yr of VIT.

Results:  Basophil CD63 activation test allowed identification of the culprit insect in 74% of honeybee venom–allergic children. In comparison, IgE reactivity was single positive in only 52% of children. Five days after starting VIT, BAT was highly comparable to before VIT. However, after 6 months and further after 2–4 yr of VIT, a significant and approximately fourfold decrease was demonstrated in CD63 response at sub-maximal 0.1 μg/ml allergen concentration, which mainly represents cellular sensitivity. No such differences were found at a higher 1 μg/ml of allergen concentration. Person-to-person analyses showed that after 2–4 yr of VIT, a marked CD63 decrease was evident in 85% of children. In addition, elevated basophil sensitivity measured before VIT was associated with the appearance of side effects observed during the build-up phase of VIT.

Conclusion:  Basophil CD63 allergen–specific sensitivity seems to be a promising tool for monitoring protective immune response in honeybee VIT.

Ancillary